Genmab Dirección

Dirección controles de criterios 3/4

El CEO de Genmab's es Jan G.J. van Winkel , nombrado en Jun 2010, tiene una permanencia de 13.83 años. compensación anual total es DKK44.30M, compuesta por 20.8% salario y 79.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.93% de las acciones de la empresa, por valor de €160.26M. La antigüedad media del equipo directivo y de la junta directiva es de 7.2 años y 7.1 años, respectivamente.

Información clave

Jan G.J. de Winkel

Chief Executive Officer (CEO)

kr.44.3m

Compensación total

Porcentaje del salario del CEO	20.8%
Permanencia del CEO	13.9yrs
Participación del CEO	0.9%
Permanencia media de la dirección	7.3yrs
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan G.J. de Winkel en comparación con los beneficios de Genmab?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr.5b
Dec 31 2023	kr.44m	kr.9m	kr.4b
Sep 30 2023	n/a	n/a	kr.4b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	kr.42m	kr.9m	kr.5b
Sep 30 2022	n/a	n/a	kr.6b
Jun 30 2022	n/a	n/a	kr.4b
Mar 31 2022	n/a	n/a	kr.2b
Dec 31 2021	kr.38m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.6b
Dec 31 2020	kr.37m	kr.7m	kr.5b
Sep 30 2020	n/a	n/a	kr.6b
Jun 30 2020	n/a	n/a	kr.6b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.35m	kr.7m	kr.2b
Sep 30 2019	n/a	n/a	kr.2b
Jun 30 2019	n/a	n/a	kr.1b
Mar 31 2019	n/a	n/a	kr.1b
Dec 31 2018	kr.28m	kr.7m	kr.1b
Sep 30 2018	n/a	n/a	kr.1b
Jun 30 2018	n/a	n/a	kr.1b
Mar 31 2018	n/a	n/a	kr.1b
Dec 31 2017	kr.27m	kr.7m	kr.1b

Compensación vs. Mercado: La compensación total de Jan G.J. van($USD6.37M) está por encima de la media de empresas de tamaño similar en el mercado Austrian ($USD4.49M).

Compensación vs. Ingresos: La compensación de Jan G.J. van ha sido consistente con los resultados de la empresa en el último año.

CEO

Jan G.J. de Winkel (62 yo)

13.9yrs

Permanencia

kr.44,300,000

Compensación

Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jan G.J. de Winkel	Co-Founder	13.9yrs	kr.44.30m	0.94% DKK 167.5m
Anthony Pagano	Executive VP & CFO	4.2yrs	kr.19.60m	0.011% DKK 1.9m
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.3yrs	kr.10.10m	sin datos
Martine van Vugt	Executive VP & Chief Strategy Officer	10.3yrs	kr.8.90m	sin datos
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	kr.800.00k	0.00060% DKK 107.2k
Tahamtan Ahmadi	Executive VP	3.2yrs	kr.19.80m	0.0048% DKK 852.2k
Mijke Zachariasse	Senior Director	no data	kr.1.10m	0.00081% DKK 144.7k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	kr.800.00k	0.00013% DKK 23.2k
Anthony Mancini	Executive VP & COO	4.2yrs	kr.19.00m	0.0044% DKK 795.0k
Andrew Carlsen	Senior Director	no data	sin datos	sin datos
Christopher Cozic	Executive VP & Chief People Officer	no data	sin datos	sin datos
Judith Klimovsky	Executive VP & Chief Development Officer	7.3yrs	kr.22.00m	0.014% DKK 2.4m

7.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GMAB es experimentado (7.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.3yrs	kr.800.00k	0.00060% DKK 107.2k
Mijke Zachariasse	Senior Director	5.2yrs	kr.1.10m	0.00081% DKK 144.7k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.3yrs	kr.800.00k	0.00013% DKK 23.2k
Anders Pedersen	Non-Independent Director	20.5yrs	kr.1.70m	0.014% DKK 2.6m
Elizabeth O'Farrell	Independent Director	2.2yrs	kr.1.90m	sin datos
Deirdre Connelly	Independent Chairman of the Board	7.2yrs	kr.2.80m	0.0089% DKK 1.6m
Rolf Hoffmann	Independent Director	7.2yrs	kr.1.50m	0.0052% DKK 929.0k
Pernille Erenbjerg	Independent Deputy Chairman	9.3yrs	kr.2.10m	0.0075% DKK 1.3m
Paolo Paoletti	Independent Director	9.3yrs	kr.1.50m	0.0032% DKK 577.1k

7.2yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de GMAB se considera experimentada (7.1 años de antigüedad promedio).

Genmab Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold €2.9m worth of stock

Genmab A/S, Annual General Meeting, Mar 13, 2024

Executive VP & CFO recently sold €220k worth of stock

Co-Founder recently sold €7.8m worth of stock

Independent Chairman of the Board recently bought €107k worth of stock

Recent updates

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold €2.9m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022)

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

New minor risk - Profit margin trend

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Executive VP & CFO recently sold €220k worth of stock

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold €7.8m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought €107k worth of stock

Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021)

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Co-Founder recently sold €7.7m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

First quarter 2022 earnings released: EPS: kr.7.10 (vs kr.16.76 in 1Q 2021)

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Insufficient new directors

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

Third quarter 2021 earnings released: EPS kr.13.61 (vs kr.8.13 in 3Q 2020)

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo